The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

CJC-1295 Dosage Guide

CJC-1295 is a GHRH analogue with a drug affinity complex (DAC) modification that extends its half-life to 6–8 days by binding to albumin. This produces sustained GH elevation rather than the pulsatile pattern of shorter GHRH analogues.

Standard Research Dosage

CJC-1295 with DAC: 1–2 mg per week, administered as a single weekly injection. CJC-1295 without DAC (Mod GRF 1-29): 100–200 mcg per injection, 2–3x daily to mimic pulsatile GH release.

DAC vs No-DAC: Key Distinction

CJC-1295 with DAC produces sustained, non-pulsatile GH elevation — sometimes called 'GH bleed.' CJC-1295 without DAC (Mod GRF 1-29) produces a sharp GH pulse and is typically combined with a GHRP like Ipamorelin for synergistic effect.

IGF-1 Elevation

Clinical studies show CJC-1295 with DAC increases IGF-1 by 200–400% above baseline with weekly dosing. This sustained IGF-1 elevation is the primary endpoint in most research protocols.